Since, E2F1 and E2F3 were prognostic makers of neuroblastoma independent of MYCN amplification and age of diagnosis, the combinations of E2F1 or E2F3 with MYCN amplification or age of diagnosis could achieve better prognostic effects in pediatric neuroblastoma patients. Here, E2F1 is linked to neuroblastoma.